The Department of Neurology and Neurological Sciences at Stanford University School of Medicine, together with multiple academic medical centers and one industry partner (Medtronic) across the US, ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...

Drawing on its leadership in advanced neurosciences, Manipal Hospital Sarjapur Road recently hosted the Manipal DBS Summit ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

The limits of standard brain stimulation For decades, doctors have used deep brain stimulation (DBS) to treat neurological ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

DBS®, an Adaptive Deep Brain Stimulation system, is now certified for commercial use across the European Economic Area (EEA) ...

Parkinson’s disease is a debilitating neurological condition that affects movement, causing tremors, stiffness and freezing ...

Newronika’s adaptive deep brain stimulation system, aDBS receives CE Mark: Milan Wednesday, July 15, 2026, 17:00 Hrs [IST] Newronika S.p.A., a Milan-based medtech company redefi ...

Medtronic has won FDA approval for a device that can help with therapy for those suffering from Parkinson’s Disease. The Dublin-based company’s BrainSense Adaptive deep brain stimulation (aDBS) and ...

Newronika S.p.A., the Milan-based medtech company redefining deep brain stimulation therapy, has received CE Mark ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...